Silvant Capital Management LLC Buys Shares of 4,033 Neurocrine Biosciences (NBIX)

Silvant Capital Management LLC bought a new stake in shares of Neurocrine Biosciences (NASDAQ:NBIX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,033 shares of the company’s stock, valued at approximately $334,000.

Other institutional investors have also made changes to their positions in the company. American International Group Inc. purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $161,000. M&T Bank Corp purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $202,000. Mission Wealth Management LP purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $204,000. Vident Investment Advisory LLC purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $207,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $230,000.

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 126,832 shares of the firm’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $80.75, for a total value of $10,241,684.00. Following the completion of the transaction, the chief executive officer now owns 473,865 shares in the company, valued at approximately $38,264,598.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Corinne H. Nevinny sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $83.13, for a total value of $415,650.00. Following the completion of the transaction, the director now owns 43,283 shares of the company’s stock, valued at approximately $3,598,115.79. The disclosure for this sale can be found here. In the last 90 days, insiders sold 207,705 shares of company stock valued at $17,485,904. 4.30% of the stock is owned by corporate insiders.

Shares of NBIX opened at $93.25 on Friday. Neurocrine Biosciences has a fifty-two week low of $41.76 and a fifty-two week high of $94.48. The company has a debt-to-equity ratio of 1.03, a quick ratio of 11.06 and a current ratio of 11.06.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, April 30th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.18). Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. The company had revenue of $71.08 million during the quarter, compared to the consensus estimate of $65.17 million. During the same quarter in the prior year, the business earned ($0.90) EPS. analysts predict that Neurocrine Biosciences will post -0.24 EPS for the current fiscal year.

Several equities research analysts recently weighed in on the company. BidaskClub raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Oppenheimer set a $100.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, February 14th. Barclays reissued an “overweight” rating and issued a $100.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, February 14th. JPMorgan Chase lifted their price objective on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Finally, Deutsche Bank lifted their price objective on Neurocrine Biosciences to $97.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Thirteen investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $102.77.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply